HiberCell Announces First Patient Dosed in Phase 1b Clinical Trial, Evaluating HC-7366 in Combination with Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia (AML) HiberCell Announces First Patient Dosed in Phase 1b Clinical Trial in AML, Evaluating HC-7366 in Combination with Venetoclax and Azacitidine

HiberCell Announces Recent Publication and Poster Presentations for its Novel GCN2 Activator, HC-7366 HiberCell Announces Recent Publication and Poster Presentations for its Novel GCN2 Activator, HC-7366

HiberCell Appoints Mark J. Mulvihill, Ph.D., Chief Scientific Officer NEW YORK, June 29, 2021 (GLOBE NEWSWIRE) -- HiberCell, a biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, today announced the appointment of Mark J....

HiberCell Initiates Phase 1a Clinical Trial of HC-5404-FU, an ER Stress Modulator NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- HiberCell, a biotechnology company dedicated to overcoming foundational barriers that prevent patients from living longer, cancer-free lives, today...

HiberCell Closes $67.4 Million Series B Financing and Secures $30 Million Debt Facility from Hercules Capital Proceeds to advance pipeline of clinical product candidates focused on preventing cancer relapse and metastasis NEW YORK, May 19, 2021 (GLOBE NEWSWIRE) -- HiberCell, a biotechnology company...